RxDoctor Payments Data

Frederick Welt, MD

Interventional Cardiology · Salt Lake City, UTNPI 1841286531

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 77.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $8,548 and has fallen 59.8% since, to $3,438 in 2025.

$26,363in general payments, 2019–2025

Across 98 payments — averaging $269.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Edwards Lifesciences$4K
  • Abbott$1K
  • Shockwave Medical, Inc$634
  • Penumbra, Inc.$127
  • Heartflow, Inc.$65
  • plus $16 from 1 others
$135,975in research payments, 2019–2025

Across 47 payments — averaging $2893.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$106K
  • Edwards Lifesciences$30K

What the payments were for

  • Consulting fees$12,00046%
  • Speaking & faculty fees$1,3505%
  • Travel & lodging$8,48332%
  • Food & beverage$4,53017%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,363 in reported general payments places this provider in the 85th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$123,009
Medicare patients
296
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$15,877
Repatha SureclickEvolocumab17$9,542
Metoprolol Succinate64$479
Atorvastatin Calcium39$353
Rosuvastatin Calcium17$155
Losartan Potassium14$131
Isosorbide Mononitrate ErIsosorbide Mononitrate11$127
Amlodipine Besylate11$71
Furosemide12$66
Spironolactone13$61
Lisinopril11$39

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →